An announcement from Cullinan Management ( (CGEM) ) is now available.
Cullinan Therapeutics has announced the initiation of a global Phase 1 clinical trial in Australia for its innovative CD19xCD3 bispecific T cell engager, CLN-978, aimed at treating systemic lupus erythematosus (SLE). This step marks a significant advancement in the company’s commitment to addressing autoimmune diseases with potential best-in-class treatments. CLN-978 is designed to be a convenient and potent off-the-shelf therapy, targeting B cells with high precision, potentially revolutionizing the standard of care for SLE patients who currently rely on lifelong immune suppression.
See more data about CGEM stock on TipRanks’ Stock Analysis page.
